Mohamed Mahmoud Nabeel

Mohamed Mahmoud Nabeel

Auto-generated profile, based on publicly available information

Mohamed Mahmoud Nabeel

Endemic Medicine Department, Faculty of Medicine, Cairo University, Giza, Egypt

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Pathogens and Global Health
Verified
Journal Article
Closed access
HSHend Ibrahim Shousha
Hend Ibrahim Shousha
AAAshraf Omar Abdelaziz
Ashraf Omar Abdelaziz
MNMohamed Mahmoud Nabeel
Mohamed Mahmoud Nabeel
DODalia Abdelhamid Omran
Dalia Abdelhamid Omran
AAAhmed Hosni Abdelmaksoud
Ahmed Hosni Abdelmaksoud
RLRania Leithy
Rania Leithy
Schistosoma mansoni infection (SMI) is suspected to be directly and indirectly involved in hepato-carcinogenesis. This study evaluated the association of a previous SMI with hepatocellular carcinoma (HCC) development, patients, tumor characteristics, treatment outcomes, and survival. This observational study included patients with HCC with and without previous SMI who presented to the multidisciplinary HCC clinic, Kasr-Alainy hospital (November 2009 to December 2019). It also included 313 patients with liver cirrhosis without HCC. Clinical and laboratory features of the patients (complete blood count, liver/renal functions , alpha-fetoprotein, and hepatitis B/C status), tumor characteristics (Triphasic CT and/or dynamic MRI), liver stiffness (transient elastography), HCC treatment outcome, and overall survival were studied. This study included 1446 patients with HCC; 688(47.6%) composed group-1, defined by patients having a history of SMI, and 758(52.4%) were in group-2 and without history of SMI. Male sex, smoking, diabetes mellitus, splenomegaly, deteriorated performance status, synthetic liver functions, and platelet count were significantly higher in group-1. The groups did not differ with regard to liver stiffness, tumor characteristics, or the occurrence of post-HCC treatment hepatic decompensation or recurrence. HCC treatment response was better in group-2. Group-1 showed lower sustained virological response to hepatitis C direct-acting antivirals (DAAs) compared with group-2 (60% versus 84.3%, respectively, P = 0.027). Prior SMI was associated with HCC (adjusted odds ratio = 1.589, 95% confidence interval = 1.187–2.127), and it was concluded that it increases the risk of HCC. In addition, it significantly affects the performance status, laboratory characteristics, response to DAAs, and overall survival.

31 July 2021 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
ZAZeinab Sayed Abdelkhalek
Zeinab Sayed Abdelkhalek
MAMohamed Abdalla
Mohamed Abdalla
MFMona Mohamed Fathy
Mona Mohamed Fathy
TETamer Mahmoud Elbaz
Tamer Mahmoud Elbaz
AAAshraf Omar Abdelaziz
Ashraf Omar Abdelaziz
MKMai Hamed Kamel
Mai Hamed Kamel
Introduction: Several micro ribonucleic acids (miRNAs) are deregulated in hepatocellular carcinoma (HCC). Others are linked to clinical pathological features of HCC. The goal of this study was to investigate whether miRNA-21 and miRNA-215 gene expression could be used as a non-invasive diagnostic tool to diagnose HCC. Methodology: The gene expression of mature miRNA -21 and miRNA -215 in serum was analysed retrospectively using singleplex TaqMan two-step stem-loop quantitative real-time reverse-transcription PCR in 40 patients with HCC, 40 with chronic hepatitis C virus (HCV) with cirrhosis and 40 apparently healthy controls. Results: Expression of miRNA -21 was significantly more down regulated in patients with HCC than in those with non-cirrhotic HCV (P = 0.007; odds ratio = 5; 95% confidence interval 1.6–15.4). The receiver operating curve analysis of the ability of miRNA-21 expression to discriminate between HCC and non-cirrhotic HCV revealed an area under the curve of 0.712 with 70% sensitivity and 68% specificity at a cut-off of ≤ 1.4468. Thus, the expression level of miRNA -21 could discriminate HCC from non-cirrhotic HCV. Significant positive correlation was observed between expression levels of microRNA-21 and miRNA -215 (r = 0.783, p < 0.001), but no association was observed between expression level of miR-215 and HCC or chronic HCV (p = 0.474). Conclusions: MiRNA-21 may be a useful, non-invasive tool for diagnosing HCC. Non-cirrhotic HCV patients have five times the risk of developing HCC when the miRNA -21 level ≤ 1.4468.

1 June 2020 in Arab Journal of Gastroenterology
Verified
Journal Article
Closed access
HSHend Ibrahim Shousha
Hend Ibrahim Shousha
RFRabab Fouad
Rabab Fouad
TETamer Mahmoud Elbaz
Tamer Mahmoud Elbaz
DSDina Sabry
Dina Sabry
MNMohamed Mahmoud Nabeel
Mohamed Mahmoud Nabeel
AAAshraf Omar Abdelaziz
Ashraf Omar Abdelaziz

9 October 2026 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
PDF file
AHAmmar Hatem
Ammar Hatem
MNMohamed Mahmoud Nabeel
Mohamed Mahmoud Nabeel
SDSamar K Darweesh
Samar K Darweesh
RZRania Zayed
Rania Zayed
AAAshraf Omar Abdelaziz
Ashraf Omar Abdelaziz
RLRania Lithy
Rania Lithy
Introduction: Sorafenib is currently among the recommended first-line medications for patients with advanced hepatocellular carcinoma (HCC); however, response to sorafenib remains unpredictable despite efforts to define prognosis. This study aims to predict treatment response and survival in patients with sorafenib-treated HCC using neutrophil-to-lymphocyte ratio (NLR), albumin-bilirubin (ALBI) grade, CRAFITY score, and Glasgow prognostic score (GPS). Methods: This prospective study recruited 75 Egyptian patients with Sorafenib-treated HCC. Pretreatment laboratory parameters and imaging studies were obtained. The neutrophil-to-lymphocyte ratio, ALBI grade, CRAFITY score, and GPS were calculated for each patient. All the patients were followed for treatment response, overall survival, and sorafenib tolerance. Results: Most of the participants were males, with a median age of 62 years. HCV was the most common underlying cause. Most of the patients had a low pretreatment NLR (77.33%), grade 2 ALBI (65.33%), 41.89% had a high CRAFITY score, and 48.6% had GPS 1. Patients were divided into two groups: group 1: sorafenib-naïve ( n = 44) and group 2: patients with previous interventional therapy ( n = 31). Pretreatment AST, ALT, mild ascites, portal invasion, and BCLC stage C were significantly higher among sorafenib-naïve patients. Median OS and time to progression for the entire cohort were 4 months and 9 months, respectively. No significant differences were observed in terms of OS between various NLR, ALBI grades, CRAFITY scores, and GPS. Multivariate analysis showed a high risk of mortality among sorafenib-intolerant patients ( p = 0.01, HR: 2.33, 95% CI: 1.23–4.42). Conclusion: Overall survival and time to progression are not affected by different pretreatment values of NLR, ALBI grade, CRAFITY score, and Glasgow prognostic score in sorafenib-treated HCC.

1 January 2026 in Hepatology Forum
Verified
Journal Article
Closed access
ARAhmed M. Ramadan
Ahmed M. Ramadan
AAAshraf Omar Abdelaziz
Ashraf Omar Abdelaziz
MNMohamed Mahmoud Nabeel
Mohamed Mahmoud Nabeel
MAMirna Atef
Mirna Atef
MKMai Hamed Kamel
Mai Hamed Kamel
HSHend Ibrahim Shousha
Hend Ibrahim Shousha
Background and Aim: The GALAD score, a mathematical model incorporating gender, age, alpha-fetoprotein (AFP), the lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and des-gamma-carboxy prothrombin (DCP), has been developed to assess the presence of hepatocellular carcinoma (HCC) in patients with chronic liver disease. This study aimed to evaluate the efficacy of the GALAD score in predicting and assessing the prognosis of hepatitis C–related HCC in patients who had received prior direct-acting antiviral (DAA) treatment. Materials and Methods: This case-control study included patients with HCV-related liver cirrhosis treated with DAAs, with or without HCC, recruited from the HCC clinic at Kasr Al-Ainy Hospital, Cairo University, and followed until death or the end of the study. Data included clinical and laboratory parameters, DCP, AFP, and AFP-L3 levels, imaging findings, treatment response, and survival. Logistic regression was used to identify independent predictors of HCC, mortality, and recurrence. Results: Eighty-eight patients with HCV-related HCC following DAA treatment and 88 patients without HCC were recruited, with no significant differences in gender or age between the groups. Participants with HCC had a higher mean GALAD score (4.32±2.47 vs. 1.32±1.46, p